Follow-Up Results from OlympiA Trial Highlight 28% Mortality Benefit with Lynparza in gBRCAm Breast Cancer

PE: The six-year follow-up from the OlympiA trial showed a 28% reduction in the risk of death with Lynparza. How does this result compare to other treatments available for gBRCAm HER2-negative high-risk early breast cancer?

Omer: The most important thing to highlight is that the Lynparza data is specific to germline BRCA- mutated (gBRCAm) patients with HER2-negative high-risk early breast cancer. This was a follow-up to earlier endpoints that we had already disseminated through the medical community. The results are really significant. What’s even more impressive is that arguably, 87.5% of patients were surviving at this point, compared to 83.2% on placebo. This matters because Lynparza is the first and only PARP inhibitor to show an overall survival benefit in early breast cancer, and it actually remains the only PARP inhibitor approved for the treatment of early breast cancer. The data is reinforcing its position as the standard-of-care for these patients. I’m also going to highlight the importance of gBRCAm testing. If patients can get tested earlier, and especially those that are at high risk, then we can intervene earlier so that patients can benefit from the data.

Full Interview Summary: The six-year follow-up data from the OlympiA trial demonstrated a 28% reduction in the risk of death with Lynparza (olaparib) for patients with germline BRCA-mutated, HER2-negative, high-risk, early-stage breast cancer. Notably, 87.5% of patients receiving Lynparza were alive at this point, compared to 83.2% on placebo, reinforcing its role as the first and only PARP inhibitor to show an overall survival benefit in early breast cancer. These findings solidify Lynparza as the standard-of-care for this patient group and emphasize the importance of early BRCAtesting to identify high-risk patients who may benefit from treatment.

Beyond triple-negative breast cancer, Lynparza demonstrated a 32% reduction in the risk of invasive disease recurrence or death in high-risk hormone receptor-positive patients, the most prevalent breast cancer subtype. These benefits were consistent across key subgroups, suggesting a broader impact on treatment strategies.

Lynparza is already approved in multiple countries, including the U.S., EU, Japan, and China, across eight indications spanning breast, ovarian, prostate, and pancreatic cancers. AstraZeneca continues to engage with regulators to expand access and explore new indications, including monotherapy and combination therapies for other PARP-dependent tumor types.

The safety profile of Lynparza, particularly in younger patients, is reassuring. Given the increasing incidence of breast cancer in younger women, early intervention is critical. The median age in the OlympiA trial was 42, and pregnancy rates were comparable between the Lynparza and placebo groups, highlighting its potential as a viable option for younger patients.